Table 8.
Number (%) of patients with treatment-related, treatment-emergent adverse events during the treatment phase by system organ class and preferred term*
| PARAMETER |
CLIN/RA GEL n=1008 |
CLINDAMYCIN GEL n=1002 |
|---|---|---|
| At least one treatment-related-emergent adverse event | 42 (4.2) | 12 (1.7) |
| Skin and subcutaneous tissue disorders | 34 (3.4) | 14 (1.4) |
| • Dry skin | 23 (2.3) | 6 (0.6) |
| • Rash scaly | 7 (0.7) | 1 (0.1) |
| • Skin burning sensation | 4 (0.4) | 1 (0.1) |
| • Erythema | 4 (0.4) | 0 |
| • Pruritus | 3 (0.3) | 1 (0.1) |
| • Skin exfoliation | 3 (0.3) | 0 |
| • Rash | 2 (0.2) | 0 |
| • Skin tightness | 0 | 2 (0.2) |
| General disorders and administration site conditions | 7 (0.7) | 0 |
| • Application site reaction | 3 (0.3) | 0 |
| • Pain | 2 (0.2) | 0 |
*
At least two patients in either treatment group